ADAM10 and neoplasm: Moreover, compared to low basal (= pre-treatment) ADAM10 expression, high basal ADAM10 expression was associated with a higher Ki67 post/pre treatment ratio (high vs. low ADAM expression, mean ratio of 1.1, 95% 0.8 to 1.3 vs. 0.7, 95% CI 0.6-0.9 respectively, p=0.02) and bigger tumor size (high vs. low ADAM10 expression, mean post/pre treatment ratio of 1.2, 95% CI 0.7-1.6 vs. 0.7, 95% CI 0.5-0.9 respectively, p=0.02) at day 21 of trastuzumab monotherapy (figure 7C, upper and lower panels).